DIAGNOSTIC TEST 126
Adalimumab
Diagnostic test for monitoring of the Adalimumab level and control of Anti-Drug Antibodies (ADA) against the drug.
Indication
Monitoring of Infliximab level and control of Anti-Drug Antibodies (ADA)
Sample material
Serum
- Minim. volume: 0,7 mL
Transport
- Within Sweden: room temperature
- International: room temperature
Method
- Drug concentration: ELISA
- Anti-Drug Antibodies (ADA): RIA
Result
Drug concentration is reported as µg/mL. At drug concentrations <5 µg/mL it is recommended to further test for ADA. ADA is reported as a concentration (AU/mL).
Interpretation
Adalimumab acts as a TNF-alpha inhibitor. The sample should be drawn at trough value. Low or unmeasurable concentration of the biologic pharmaceutical is associated with poor clinical effect. One explanation can be that anti-drug antibodies (ADA) block the effect and enhance clearance of the drug.
Need pricing information?
How to order
This test is available worldwide for hospitals, clinics, and physicians.
-
Print and complete the request form
Download the request form. Clearly state the name and phone number of the referring hospital, clinic, or physician. -
Prepare your samples
Serum: At least 0.7 mL serum (plain serum tubes without additives).
-
Send samples and request form
Within Sweden
Samples can be sent at room temperature to:
Envelopes and smaller boxes:
Wieslab AB, Box 50117, 20211 Malmö, Sweden
Larger boxes and frozen samples:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
International
Send samples cold to:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
Last updated: 2025-08-18
